EP1377312A4 - Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese - Google Patents

Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese

Info

Publication number: EP1377312A4
Authority: EP; European Patent Office
Prior art keywords: anthrax; angiogenesis; tumor growth; inhibiting tumor; lethal factor
Prior art date: 2001-03-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP02725277A

Other languages

German (de)

English (en)

Other versions

EP1377312A1 (fr

Inventor

Nicholas S Duesbery

Craig P Webb

Woude George F Vande

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

VAN ANDEL INSTITUTE

ANDEL INST VAN

Original Assignee

VAN ANDEL INSTITUTE

ANDEL INST VAN

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-22

Filing date

2002-03-22

Publication date

2004-10-06

2002-03-22 Application filed by VAN ANDEL INSTITUTE, ANDEL INST VAN filed Critical VAN ANDEL INSTITUTE

2004-01-07 Publication of EP1377312A1 publication Critical patent/EP1377312A1/fr

2004-10-06 Publication of EP1377312A4 publication Critical patent/EP1377312A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP02725277A 2001-03-22 2002-03-22 Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese Withdrawn EP1377312A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US27762501P	2001-03-22	2001-03-22
US277625P		2001-03-22
PCT/US2002/008656 WO2002076496A1 (fr)	2001-03-22	2002-03-22	Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese

Publications (2)

Publication Number	Publication Date
EP1377312A1 EP1377312A1 (fr)	2004-01-07
EP1377312A4 true EP1377312A4 (fr)	2004-10-06

Family

ID=23061685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02725277A Withdrawn EP1377312A4 (fr)	2001-03-22	2002-03-22	Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese

Country Status (4)

Country	Link
EP (1)	EP1377312A4 (fr)
AU (1)	AU2002255852B2 (fr)
CA (1)	CA2442015A1 (fr)
WO (1)	WO2002076496A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020054869A1 (en)	2000-09-01	2002-05-09	Han-Mo Koo	Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
NZ518726A (en)	2001-05-09	2004-06-25	Warner Lambert Co	Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20070116687A1 (en) *	2003-05-13	2007-05-24	Medvet Science Pty, Ltd.	Method of modulating cellular transmigration and agents for use therein
WO2005007193A2 (fr) *	2003-07-07	2005-01-27	Vande Woude, George, F.	Inhibition de l'angiogenese tumorale par combinaison de la thrombospondine-1 et des inhibiteurs du facteur de croissance endotheliale vasculaire
AU2004283148A1 (en)	2003-10-21	2005-05-06	Warner-Lambert Company Llc	Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
UA89035C2 (ru)	2003-12-03	2009-12-25	Лео Фарма А/С	Эфиры гидроксамовых кислот и их фармацевтическое применение
AT504159A1 (de) *	2006-08-16	2008-03-15	Marlyn Nutraceuticals Inc	Verwendung von proteasen
WO2009132397A1 (fr) *	2008-05-01	2009-11-05	University Of South Australia	Procédés et agents pour la modulation du taux et/ou de l'activité de la protéine hif-2 alpha
EP2701694A4 (fr) *	2011-04-28	2014-10-08	Univ Duke	Procédés de traitement d'hémoglobinopathies
WO2013082511A1 (fr) *	2011-12-02	2013-06-06	Genentech, Inc.	Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
WO2014081760A1 (fr)	2012-11-20	2014-05-30	Duke University	Procédés de traitement d'hémoglobinopathies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6147107A (en) *	1998-12-20	2000-11-14	Virginia Commonwealth University	Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5405941A (en) *	1993-04-15	1995-04-11	National Jewish Center For Immunology And Respiratory Medicine	MEKK protein, capable of phosphorylating MEK
US5525625A (en) *	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
GB2323845A (en) *	1997-03-31	1998-10-07	Merck & Co Inc	MEK inhibiting lactones
CA2290506C (fr) *	1997-07-01	2005-12-27	Warner-Lambert Company	Derives d'acide benzhydroxamique phenylamino 4-bromo ou 4-iodo et utilisation de ces derniers en tant qu'inhibiteurs de mek
US6485925B1 (en) *	1998-04-01	2002-11-26	The United States Of America As Represented By The Department Of Health And Human Services	Anthrax lethal factor is a MAPK kinase protease
DE69928568T2 (de) *	1998-12-22	2006-07-27	Warner-Lambert Co. Llc	Chemotheriapie mit einem antimitotischen mittel und einem mek inhibitor
DE69926914T2 (de) *	1999-01-13	2006-06-29	Warner-Lambert Co. Llc	1-heterozyklus-substituierte diarylaminen
BR9916894A (pt) *	1999-01-13	2001-11-20	Warner Lambert Co	ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
AU3761400A (en) *	1999-03-19	2000-10-09	Du Pont Pharmaceuticals Company	Amino-thio-acrylonitriles as mek inhibitors
CA2362705A1 (fr) *	1999-03-19	2000-09-28	Joseph B. Santella, Iii	N-adamant-1-yl-n'-¬4-chlorobenzothiazol-2-yl\| uree utilisee dans le traitement des inflammations et comme agent de radiosensibilisation anticancereux
GB9910577D0 (en) *	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
GB9910580D0 (en) *	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds

2002
- 2002-03-22 WO PCT/US2002/008656 patent/WO2002076496A1/fr not_active Ceased
- 2002-03-22 CA CA002442015A patent/CA2442015A1/fr not_active Abandoned
- 2002-03-22 AU AU2002255852A patent/AU2002255852B2/en not_active Ceased
- 2002-03-22 EP EP02725277A patent/EP1377312A4/fr not_active Withdrawn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6147107A (en) *	1998-12-20	2000-11-14	Virginia Commonwealth University	Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 306a, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2000 (2000-11-16), BONATI ANTONIO ET AL: "Selective inhibition of MEK1 kinase downmodulates ERK activity and proliferation of AML blasts", XP002279051, Database accession no. PREV200100301863 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), PRICE DAVID T ET AL: "Activation of extracellular signal-regulated kinase in human prostate cancer", XP002279050, Database accession no. PREV199900481092 *
JOURNAL OF UROLOGY, vol. 162, no. 4, October 1999 (1999-10-01), pages 1537 - 1542, ISSN: 0022-5347 *
See also references of WO02076496A1 *

Also Published As

Publication number	Publication date
AU2002255852B2 (en)	2006-11-09
CA2442015A1 (fr)	2002-10-03
WO2002076496A1 (fr)	2002-10-03
EP1377312A1 (fr)	2004-01-07

Publication	Publication Date	Title
FR20C1039I2 (fr)	2021-08-13	Derives de l'uk-2a
EP1432527A4 (fr)	2007-01-31	Regulation biologique de nanoparticules
DE69822669D1 (de)	2004-04-29	Verminderung des haarwuchses
EP1037641A4 (fr)	2005-02-09	Leurre du facteur de transcription et inhibiteur de la croissance tumorale
EP1357809A4 (fr)	2005-01-26	Produits alimentaires aseptises
FR2831769B1 (fr)	2004-07-30	Facteur d'appetence et exhausteur de gout
GB0130789D0 (en)	2002-02-06	Application of spores
CY2006003I1 (el)	2009-11-04	Χρηση δαπτομυκινης
EP1420807A4 (fr)	2005-08-17	Protection du facteur de croissance derive de plaquettes du myocarde
DE69934510D1 (de)	2007-02-01	Verminderung des haarwuchses
EP1377312A4 (fr)	2004-10-06	Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese
HUP0401589A3 (en)	2005-11-28	New peptides - analogs of human growth hormone-releasing hormone
PT1401283E (pt)	2008-03-07	Controlo biológico de doenças de plantas
NO20024578L (no)	2002-11-20	Inhibering av angiogenese og tumorvekst
EP1100887A4 (fr)	2003-01-15	Facteur 11 de differentiation de croissance
NO20034972D0 (no)	2003-11-07	Behandling av ADHD
NO20035668D0 (no)	2003-12-18	Antitumorformuleringer av tioxantenon
ITMI20000779A0 (it)	2000-04-11	Apparecchiatura per la produzione e/o lavorazione di pezzi tubolari
GB0410147D0 (en)	2004-06-09	Human angiomotin-like protein 1
ITMI20010851A0 (it)	2001-04-23	Composizione antiparassitaria e metodo di trattamento antiparassitario utilizzante la composizione
TW499838U (en)	2002-08-21	Improved structure of water-absorbent flowerpot
TW516367U (en)	2003-01-01	Structure improvement of double-layered water-storage-type flowerpot
AU2001250405A1 (en)	2001-10-08	Regulation of human adp-ribosylation factor-related protein
GB0415327D0 (en)	2004-08-11	Human prostrate cancer candidate protein 1
FI20010739A0 (fi)	2001-04-10	Löylynhajoituselin

Legal Events

Date	Code	Title	Description
2003-11-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-01-07	17P	Request for examination filed	Effective date: 20031007
2004-01-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2004-01-07	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2004-10-06	A4	Supplementary search report drawn up and despatched	Effective date: 20040823
2008-04-23	17Q	First examination report despatched	Effective date: 20080320
2010-02-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2010-03-24	18D	Application deemed to be withdrawn	Effective date: 20091001